Да Bomb

  • by: |
  • 06/05/2012

Da bomb

Last week I testified in front of the Russian Duma’s committee on non-communicable diseases (NCDs). That committee is preparing (at President Putin’s direction) a series of recommendations to address the many significant health issues that NCDs pose to the Russian Federation (with smoking at the top of the list).

Here are my remarks (as presented):

NCDs (such cancer, diabetes, Alzheimer’s Disease, chronic lung and heart disease) are the leading causes of death and disease worldwide, killing more than 36 million people in 2008, and are projected to increase by 15% globally between 2010 and 2020 due in large part to progress made in combating infectious diseases through economic growth, development, and better treatment options.

But this frightening increase it is also largely linked to lifestyle choices.

For most infectious diseases, rapid access to diagnosis and treatment is an imperative for patient survival.

But for NCDs the “lifecycle” is different, and there may be many actions that can take place, such as prevention, before medicines or other treatments need to be prescribed. A major epidemiological shift is underway.

The bad news is that NCDs sit at the center of a complex series of social and economic factors that it is hard to influence from the top down.

The good news is that there are many inexpensive and proven preventative medical interventions that can significantly reduce the burden of NCDs.

A neglected area of discussion within the NCD debate is medical research and development, which has the very real promise of introducing cures for currently incurable chronic conditions, as well as treatments for diseases where there is currently a lack of pharmaceutical options.

Just as innovation in HIV/AIDS treatment has turned it from a terminal disease into a manageable chronic condition, it is not entirely unfeasible that future innovation will throw up a cure or prophylactic vaccine for many diseases currently considered as “chronic.”

The current trend of increase in Alzheimer’s, for example, threatens to overwhelm health systems in OECD countries because not much can be done beyond labor-intensive care. If a cure were invented, this huge economic burden would be significantly reduced as would much pain and suffering.

Remember that tuberculosis used to be an incurable major chronic disease until the invention of treatments. Innovation is crucial – but it is not the only tool available to us in the war against NCDs.

Fortunately for NCDs, there are plenty of off-patent and widely available preventative medicines (such as statins and medicines for diabetes and hypertension) that can dramatically reduce the overall disease burden

The good news is that half of deaths caused each year by NCDs are preventable and lifestyle choices, such as unhealthy diet and tobacco use, are part of the explanation. Reducing disability or deaths through increased investment in prevention programs will contribute to higher economic growth and allow limited resources to be focused efficiently on patients most in need.

Money is tight everywhere. Before governments agree to increased spending on top-down schemes, it is worth taking a look back at the last major global effort to fight disease: HIV/AIDS.

Some lessons are clear, like the need to focus on prevention. The UN’s big mistake with HIV/AIDS was to prioritize treatment. This neglect of prevention led to new infections piling up more quickly than they could be treated, creating unnecessary suffering and costs. Actions on access and affordability of NCD treatments include promoting the right policy, along with smart regulatory and supply chain environments that secure optimal quality of care for patients.

But in order to accomplish this, there must be a confluence of interests.” And the good news is that there is.

There is no substitute for the power of partnership. It’s not about having pharmaceutical companies write checks, but rather combining the resources of private industry with the expertise of leading global health organizations, to identify new models of patient care that increases access and speed to treatment – and not just medicines.

Part of the role of government is to facilitate partnerships that propel progress. In the United States we’re learning that, in the battle against NCDs our health systems needs to get smarter, specifically: 

·      Our reimbursement systems need to be less focused on outputs and more on individual patient outcomes;

·      Health professional education should be more holistic addressing all issues concerning both acute and chronic conditions;

·      Our view of drug safety relative to what is Rx vs. OTC is going to have to change (such as OTC statins and HIV/AIDS preventative medicines);

·      Our delivery systems will have to dramatically reform to take advantage of new e-health technologies; 

·      The partnership between social services and health services will have to become closer (including smoking cessation and weight reduction strategies), and 

·      Many aspects of our healthcare system need to be decentralized as far as possible to the local level – thus making it easier to deal with complexity of multi-chronic conditions.

Most importantly, we must place personal responsibility at the center of the NCD debate – because it is the most effective way to ensure that early detection and prevention is maximized whenever and wherever possible.

I look forward to working with you in your efforts to create a US/Russian Healthcare Foundation that will help both of our countries and all of its citizens live longer, healthier and more productive lives.

Thank you.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog